Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Myqorzo et Redemplo approuvés en Chine Approbation de Myqorzo pour la cardiomyopathie hypertrophique obstructive et de Redemplo pour le syndrome de chylomicronémie familiale.Souligne l’engagement...
-
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi’s long-term commitment to...
-
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
-
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
-
The NFT in healthcare market size is projected to expand from USD 211.26 million in 2024 to USD 1142.77 million by 2034, with a CAGR of 18.34%.
-
Dublin, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The "Achromatopsia Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Achromatopsia Market is experiencing...
-
Austin, TX, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “T-Cell Engagers Market Size, Trends and Insights By Product Type (BiTEs...
-
Austin, TX, USA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neurocosmetics Market Size, Trends and Insights By Product Type (Body Care, Face...
-
The protein therapeutics market is anticipated to grow from USD 375.3 billion in 2024 to USD 740.07 billion by 2034, achieving a CAGR of 7.08%.
-
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...